IL164438A0 - Sustaubed release of guaifenesin combination drugs - Google Patents
Sustaubed release of guaifenesin combination drugsInfo
- Publication number
- IL164438A0 IL164438A0 IL16443803A IL16443803A IL164438A0 IL 164438 A0 IL164438 A0 IL 164438A0 IL 16443803 A IL16443803 A IL 16443803A IL 16443803 A IL16443803 A IL 16443803A IL 164438 A0 IL164438 A0 IL 164438A0
- Authority
- IL
- Israel
- Prior art keywords
- sustaubed
- release
- combination drugs
- guaifenesin
- guaifenesin combination
- Prior art date
Links
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 title 1
- 229940000425 combination drug Drugs 0.000 title 1
- 229960002146 guaifenesin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/121,706 US6955821B2 (en) | 2000-04-28 | 2002-04-15 | Sustained release formulations of guaifenesin and additional drug ingredients |
| US10/406,557 US7838032B2 (en) | 2000-04-28 | 2003-04-04 | Sustained release of guaifenesin |
| US10/406,574 US7985420B2 (en) | 2000-04-28 | 2003-04-04 | Sustained release of guaifenesin combination drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL164438A0 true IL164438A0 (en) | 2005-12-18 |
Family
ID=29255202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16443803A IL164438A0 (en) | 2002-04-15 | 2003-04-15 | Sustaubed release of guaifenesin combination drugs |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1503739A4 (en) |
| JP (1) | JP5466346B2 (en) |
| CN (1) | CN1655766B (en) |
| AU (1) | AU2003237807B2 (en) |
| CA (1) | CA2481739C (en) |
| EA (1) | EA007156B1 (en) |
| IL (1) | IL164438A0 (en) |
| MX (1) | MXPA04010225A (en) |
| WO (1) | WO2003088952A1 (en) |
| ZA (1) | ZA200409171B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20040134A1 (en) | 2002-07-25 | 2004-03-06 | Pharmacia Corp | PRAMIPEXOL ONCE-A-DAY DOSAGE FORM |
| JP2007517766A (en) * | 2003-09-24 | 2007-07-05 | コンビナトアールエックス インコーポレーティッド | Treatment for administering a combination of drugs |
| CA2476101A1 (en) * | 2004-08-12 | 2006-02-12 | Bernard Charles Sherman | Extended-release capsules comprising venlafaxine hydrochloride |
| NZ589267A (en) * | 2004-08-13 | 2012-06-29 | Boehringer Ingelheim Int | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| HUE025173T2 (en) | 2005-12-13 | 2016-01-28 | Incyte Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
| CN1994285B (en) * | 2006-01-04 | 2011-03-16 | 上海医药工业研究院 | Sustained release micro-pellet of guaifenesin and preparation process thereof |
| WO2008089260A2 (en) * | 2007-01-16 | 2008-07-24 | Victory Pharma, Inc. | Combined administration of benzonatate and guaifenesin |
| CN101658507B (en) * | 2008-08-26 | 2011-12-07 | 北京科信必成医药科技发展有限公司 | Glyceryl guaiacolate and pseudoephedrine compound sustained release preparation |
| BRPI1007484B1 (en) | 2009-02-04 | 2019-04-16 | Astellas Pharma Inc. | PHARMACEUTICAL COMPOSITION FORMED ORAL ADMINISTRATION UNDERSTANDING A LAYER UNDERSTANDING A MODIFIED RELEASE PART AND A LAYER UNDERSTANDING AN IMMEDIATE RELEASE PART |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| US9339478B2 (en) | 2011-02-04 | 2016-05-17 | Reckitt Benckiser Llc | Pharmaceutical formulation |
| ES2560611T3 (en) | 2011-06-20 | 2016-02-22 | Incyte Holdings Corporation | Phenyl azetidinyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| CN102755304A (en) * | 2012-08-03 | 2012-10-31 | 四川百利药业有限责任公司 | Preparation method of guaifenesin and dextromethorphan hydrobromide capsules |
| SG10202111768XA (en) | 2012-11-15 | 2021-11-29 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| CN114010611B (en) | 2013-08-07 | 2023-11-28 | 因赛特控股公司 | Sustained release dosage forms of JAK1 inhibitors |
| GB201506755D0 (en) | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
| CN105982860B (en) * | 2015-02-11 | 2020-04-14 | 北京科信必成医药科技发展有限公司 | Guaifenesin Anhydrous Swallow Taste Masking Granules |
| WO2017062997A1 (en) | 2015-10-09 | 2017-04-13 | Reckitt Benckiser Llc | Pharmaceutical formulation |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4552899A (en) * | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
| US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
| ATE424810T1 (en) * | 1998-12-11 | 2009-03-15 | Nostrum Pharmaceuticals Inc | A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER |
| CA2383405A1 (en) * | 1999-09-14 | 2001-03-22 | Smithkline Beecham Corporation | Process for making aqueous coated beadlets |
| US6372525B1 (en) * | 1999-12-20 | 2002-04-16 | Taiwan Semiconductor Manufacturing Company | Wafer-level antenna effect detection pattern for VLSI |
| US6372252B1 (en) * | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
| US20020022058A1 (en) * | 2000-07-08 | 2002-02-21 | Lovercheck Dale R. | Unit dose of material in system and method |
-
2003
- 2003-04-15 CA CA2481739A patent/CA2481739C/en not_active Expired - Lifetime
- 2003-04-15 WO PCT/US2003/011500 patent/WO2003088952A1/en not_active Ceased
- 2003-04-15 EA EA200401369A patent/EA007156B1/en not_active IP Right Cessation
- 2003-04-15 AU AU2003237807A patent/AU2003237807B2/en not_active Ceased
- 2003-04-15 JP JP2003585704A patent/JP5466346B2/en not_active Expired - Fee Related
- 2003-04-15 CN CN038125110A patent/CN1655766B/en not_active Expired - Fee Related
- 2003-04-15 MX MXPA04010225A patent/MXPA04010225A/en active IP Right Grant
- 2003-04-15 EP EP03736462A patent/EP1503739A4/en not_active Ceased
- 2003-04-15 IL IL16443803A patent/IL164438A0/en unknown
-
2004
- 2004-11-11 ZA ZA2004/09171A patent/ZA200409171B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5466346B2 (en) | 2014-04-09 |
| EA200401369A1 (en) | 2005-06-30 |
| ZA200409171B (en) | 2005-07-27 |
| AU2003237807B2 (en) | 2008-10-23 |
| AU2003237807A1 (en) | 2003-11-03 |
| CN1655766A (en) | 2005-08-17 |
| CA2481739C (en) | 2012-10-02 |
| CA2481739A1 (en) | 2003-10-30 |
| CN1655766B (en) | 2012-05-30 |
| EP1503739A4 (en) | 2006-06-21 |
| WO2003088952A1 (en) | 2003-10-30 |
| EA007156B1 (en) | 2006-08-25 |
| EP1503739A1 (en) | 2005-02-09 |
| MXPA04010225A (en) | 2005-07-05 |
| JP2005528402A (en) | 2005-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL164438A0 (en) | Sustaubed release of guaifenesin combination drugs | |
| IL236190A0 (en) | Sustained release of antiinfectives | |
| PL373914A1 (en) | Immediate release dosage forms containing solid drug dispersions | |
| GB0225030D0 (en) | Medicinal compounds | |
| EG24479A (en) | Modified release pharmaceutical formulation | |
| EP1553925A4 (en) | Modified release oral dosage form | |
| AU2003260803A8 (en) | Sustained release pharmaceutical composition | |
| PL377495A1 (en) | Solid drug for oral use | |
| AU2003284634A1 (en) | Sustained release drug carrier | |
| PL376840A1 (en) | Prolonged release pharmaceutical composition | |
| EP1895991A4 (en) | Modified release formulations of anti-irritability drugs | |
| GB0202900D0 (en) | Novel formulations of drugs | |
| IL165069A0 (en) | Immediate release pharmaceutical formulation | |
| IL173738A0 (en) | Modafinil modified release pharmaceutical compositions | |
| IL176222A0 (en) | Sustained release torsemide dosage forms | |
| IL163887A0 (en) | Controlled release dosage forms | |
| EP1478353A4 (en) | Sustained release pharmaceutical composition | |
| EP1484061A4 (en) | Drugs containing riboflavin-type compounds | |
| EP1501844A4 (en) | Disaccharides for drug discovery | |
| GB0206505D0 (en) | Pharmaceutical combination | |
| GB2401043B (en) | Drug | |
| PL373409A1 (en) | Pharmaceutical combination | |
| GB0327742D0 (en) | Novel uses of known drugs | |
| IL176061A0 (en) | Nitrooxyderivatives of antihypertensive drugs | |
| PL355453A1 (en) | Pharmaceutical agent |